Effect of atorvastatin on stroke in patients with type 2 diabetes: factors predicting the risk of stroke in the Collaborative Atorvastatin Diabetes Study (CARDS)

Effect of atorvastatin on stroke in patients with type 2 diabetes: factors predicting the risk of stroke in the Collaborative Atorvastatin Diabetes Study (CARDS)

Detalles Bibliográficos
Main Authors:	Hitman, G, Newman, C, Szarek, M, Colhoun, H, Betteridge, J, Durrington, P, Neil, A, Livingstone, S, Fuller, J, Investigators, CARDS
Formato:	Conference item
Publicado:	2005

Títulos similares

Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS).
por: Hitman, G, et al.
Publicado: (2007)

Effect of atorvastatin on stroke in the collaborative atorvastatin diabetes study (CARDS): Factors predictive of the risk of stroke
por: Newman, C, et al.
Publicado: (2005)

Safety of atorvastatin in the collaborative AtoRvastatin diabetes study (CARDS)
por: Newman, C, et al.
Publicado: (2006)

The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS).
por: Newman, C, et al.
Publicado: (2008)

Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS).
por: Colhoun, H, et al.
Publicado: (2005)

Effect of atorvastatin in patients 65 years of age with type 2 diabetes: Subgroup analysis from the collaborative atorvastatin diabetes study (CARDS)
por: DeMicco, D, et al.
Publicado: (2005)

Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes.
por: Thomason, M, et al.
Publicado: (2004)

Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
por: Colhoun, H, et al.
Publicado: (2009)

Change in Lp-PLA2 With Risk Change on Statin Therapy in the Collaborative Atorvastatin Diabetes Study (CARDS)
por: Betteridge, D, et al.
Publicado: (2009)

Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS).
por: Charlton-Menys, V, et al.
Publicado: (2009)

Erratum: Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: The Collaborative Atorvastatin Diabetes Study (CARDS)
por: Charlton-Menys, V, et al.
Publicado: (2009)

Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS).
por: Raikou, M, et al.
Publicado: (2007)

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
por: Colhoun, H, et al.
Publicado: (2004)

Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes.
por: Colhoun, H, et al.
Publicado: (2002)

Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS).
por: Charlton-Menys, V, et al.
Publicado: (2009)

Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).
por: Neil, H, et al.
Publicado: (2006)

Cost-effectiveness of atorvastatin (10mg) in patients with type 2 diabetes without coronary heart disease: CARDS trial analysis and extrapolation
por: Raikou, M, et al.
Publicado: (2005)

The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease.
por: Soedamah-Muthu, S, et al.
Publicado: (2003)

C-reactive Protein and Amyloid A as Predictors of Cardiovascular Events in Type 2 Diabetes in CARDS
por: Charlton-Menys, V, et al.
Publicado: (2009)

The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease
por: Soedamah-Muthu, S, et al.
Publicado: (2011)

The effectiveness of atorvastatin in the prevention of stroke
por: O. D. Ostroumova, et al.
Publicado: (2015-12-01)

Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial.
por: Colhoun, H, et al.
Publicado: (2011)

Combination therapy of atorvastatin and probucol on ischemic stroke in clinic
por: Yan Tao, et al.
Publicado: (2012-10-01)

Atorvastatin in stroke: a review of SPARCL and subgroup analysis
por: Branko N Huisa, et al.
Publicado: (2010-03-01)

The Effect of Atorvastatin on Inslin Resistance in Patients with Type Two Diabetes
por: Afsaneh Talaei, et al.
Publicado: (2019-06-01)

The Effect of Atorvastatin on Inflammatory Markers in Patients with Type Two Diabetes
por: Afsaneh Talaei, et al.
Publicado: (2018-08-01)

Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)
por: Harshal A. Deshmukh, et al.
Publicado: (2012-05-01)

The Effects of Atorvastatin on Arterial Stiffness in Male Patients with Type 2 Diabetes
por: Colin Davenport, et al.
Publicado: (2015-01-01)

Therapeutic Response of Serum Lipids to Atorvastatin in Type II Diabetic Patients
por: Riyadh M. Murtadha
Publicado: (2017-03-01)

Therapeutic Response of Serum Lipids to Atorvastatin in Type II Diabetic Patients
por: Riyadh M. Murtadha
Publicado: (2017-02-01)

Comparative Effectiveness of Rosuvastatin Versus Atorvastatin in Acute Ischemic Stroke Treatment
por: Joon‐Tae Kim, et al.
Publicado: (2025-02-01)

ANTIATHEROGENIC AND PLEIOTROPIC ACTIVITY OF VARIOUS DOSES OF ATORVASTATIN IN PATIENTS WITH ISCHEMIC STROKE
por: M. G. Bubnova, et al.
Publicado: (2013-08-01)

Gene Polymorphisms Affect the Effectiveness of Atorvastatin in Treating Ischemic Stroke Patients
por: Yun-Hua Yue, et al.
Publicado: (2016-07-01)

Statines in treatment of patients with diabetes mellitus: niche of atorvastatine
por: S. A. Urazgildeeva
Publicado: (2018-03-01)

FREQUENCY AND CORRELATES OF MYOPATHY IN PATIENTS WITH DIABETES TAKING ATORVASTATIN
por: Kamil Rehman Butt, et al.
Publicado: (2021-04-01)

Atorvastatin ascorbic acid cocrystal strategy to improve the safety and efficacy of atorvastatin
por: Sunil Kumar Karumuri Taraka, et al.
Publicado: (2022-04-01)

Atorvastatin reduces β-Adrenergic dysfunction in rats with diabetic cardiomyopathy.
por: Aude Carillion, et al.
Publicado: (2017-01-01)

Evaluation of the effects of atorvastatin on renal ischemia-reperfusion in diabetic rats
por: Leila Pirmoradi, et al.
Publicado: (2020-11-01)

The Effect of Atorvastatin on the Common Carotid Artery Intima-Media Thickness in Patients with Ischemic Stroke
por: Mojtaba Khazaei, et al.
Publicado: (2020-01-01)

Polymorphisms of the apolipoprotein E gene affect response to atorvastatin therapy in acute ischemic stroke
por: QianQian Bi, et al.
Publicado: (2022-11-01)